Introduction {#s1}
============

At the end of 2019, a novel coronavirus (CoV) unexpectedly has been detected in Wuhan, a city of China. Then the new coronavirus rapidly infected in every province of China with the passengers traveling ([@B20]). On 12^th^ January, 2020, the world health organization (WHO) named the coronavirus disease as "2019-nCoV". A few days later, the disease was listed as a public health emergency of international concern. On 11^th^ February, 2020, WHO re-named it as COVID-19 for the disease ([@B5]). The new name is taken from the word "corona", "virus", and "disease", with 2019 representing the year that it emerged. On the late June 2020, tens of thousands cases and several thousand deaths have been reported in China alone, while thousands of cases in other countries ([@B35]). This emerging viral infection was associated with severe human respiratory disease with a \~2--3% fatality rate according to the current report ([@B23]). Until now, COVID-19 has been reported in South Korea, Japan, Thailand, Malaysia, Singapore, Italy, Unite State America and so on ([@B39]). Since the outbreak of the COVID-19 in the whole world, the prevention and treatment of the epidemic is severe, complicated, and arduous.

The COVID-19 has been considered to be a new human-infecting betacoronavirus, which shows a high similarity with the genome sequence of severe acute respiratory syndrome (SARS) coronavirus, SARS-CoV and SARS-like CoVs ([@B15]). According to reports of the pneumonia cases in China, COVID-19 infection causes severe acute respiratory syndrome with major symptoms such as fever, cough, myalgia, or fatigue. Meanwhile the chest radiographs of patients have been revealed invasive lesions in both lungs ([@B68]). A great deal of effort has been made to prevent the virus spread rapidly in China. Firstly, most of the provinces in China were launched an emergency response plan for public health emergencies to carry out specific prevention and control measures. Then, 13 cities, such as Wuhan, HuangGang, XiaoGan, and so on, in Hubei province where the virus is most severe, have been made out the strategy of lock-down according to the reports of Hubei provincial health and fitness commission.

In the face of the rapid development of this epidemic, how to improve the cure rate, find effective drugs against the virus, has been the most urgent problem. CQ was found to block COVID-19 infected Vero E6 cells *in vitro* ([@B3]), with a 90%-maximal effective concentration (EC~90~) of 6.9 μM ([@B65]), which can be clinically achievable in rheumatoid arthritis patients who usually received 500 mg administration. Consequently, CQ as an achievable and potential candidate drug to conquer the new coronavirus has been put into action in clinical trials in China. So far, the number of clinical trials with CQ against COVID-19 is fourteen in China, which have never been published before. Naturally, the analog of CQ, hydroxychloroquine (HCQ), shall be gained attention for scientists. Although the price of HCQ is more expensive than CQ, the toxic are lower than CQ ([@B40]). Eleven programs of HCQ against COVID-19 have also been carried out in China.

The aim of this paper was to discuss and summarize the progress of effects from CQ and HCQ against COVID-19 and its potential risk in clinic use. We searched the CNKI and Wangfang databases in Chinese language to identify published reports with the keywords used for literature research included "coronavirus, chloroquine, hyroxychloroquine" in alone or in combined. The same way was carried out in PubMed, EMBASE, and Ovid databases in English language. We also searched the website of Chinese Clinical Trial Registry (<http://www.chictr.org.cn/> ) till the day on 27^th^, June, 2020. Finally, we hope this study could provide important evidence for rational use of CQ and HCQ against this unexpected disease.

Results and Discussion {#s2}
======================

Brief Introduction of the Origin of CQ and HCQ {#s2_1}
----------------------------------------------

CQ was originated from quinine, which was short-acting alkaloid drug extracted from cinchona bark and was the first drug used widely for malaria from the 19th century ([@B53]). Quinine remained the mainstay of treating malaria until the 1920s with the obstacle of its poor tolerability, poor compliance with complex dosing regimens and adverse effects with its use ([@B48]). Due to these challenges, CQ, as the most important derivate from quinine, was extensively used, especially beginning in the 1940s ([@B69]). With extensive use, the adverse reaction of CQ, especially in retinal toxicity and ophthalmologic adverse symptom was obvious ([@B43]). Then HCQ, which aimed to is proved to be threefold less toxic than CQ ([@B40]) was designed. Both of the two drugs have a flat aromatic core structure and are weak bases due to the presence of a basic side chain. The basic side chain is thought to contribute to the accumulation of these drugs in intracellular compartments, especially lysosomal compartments, which verifies to be crucial for the potential interaction with nucleic acids ([@B2]). The 3D structure of CQ and HCQ is exhibited in [**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}. Neither CQ nor HCQ underwent conventional drug developments, the usage of them were broaden to anti-virus, anti-cancer, anti-rheumatoid arthritis, and so on.

![The 3D structure of CQ.](fphar-11-01167-g001){#f1}

![The 3D structure of HCQ.](fphar-11-01167-g002){#f2}

Brief Introduction of CQ on the Virus {#s2_2}
-------------------------------------

CQ is considered to be an antimalarial drug for so many years, which clinic history could be traced back to 1820 ([@B10]). The 3D structure of CQ is shown in [**Figure 1**](#f1){ref-type="fig"}. With French famous pharmacists successfully extracting from cinchona, quinine is the earliest antimalarial for treatment of febrile diseases in the history. In 1930's, German scientists synthesized the CQ with lower toxicity and stronger effect than quinine ([@B66]). The development of CQ against virus was shown in [**Figure 3**](#f3){ref-type="fig"}, meanwhile the potential mechanism was exhibited correspondingly in [**Table 1**](#T1){ref-type="table"}. As shown in [**Table 1**](#T1){ref-type="table"} and [**Figure 3**](#f3){ref-type="fig"}, the group of Daniel Gonzalez-Dunia used CQ in 1998 ([@B28]), as a lysosomotropic agent, to inhibit the borna disease virus infection. The mechanism of borna disease virus entry into C6 rat glioma cells were involved in pH-dependent fusion after internalization of the virion by endocytosis, while CQ could prevent endosomal acidification to inhibit the entry of borna disease virus. At the end of 2002, SARS coronavirus was broken out ([@B9]). Consequently, CQ was verified effect effectively to inhibit the infection and transmission of SARS-CoV *via* increasing endosomal pH, as well as interfering with the glycosylation of cellular receptors of SARS-CoV ([@B63]). Also, the similar function was observed in avian leukemia virus (ALV) by CQ ([@B18]), which accumulates in endocytic compartments and increases the endosomal pH to reduce the entry of pseudotyped ALV type B. Then in 2006, CQ had been shown to be effective in human immunodeficiency virus type 1 (HIV) ([@B56]). With the progress of experimental technology and methodological approaches, the effect of CQ *via* autophagy inhibition were got extensive attention worldwide ([@B58]). The resurgence of Chikungunya virus (CHIKV) in India and the Indian Ocean islands associated with severe clinical symptoms also made great public health concern in 2007 ([@B38]). After a series of experiments, the scientists in India suggested the mechanism of CQ to inhibit the CHIKV infection in Vero cells involving the early stages of infection in 2010 ([@B32]). And the scientists confirmed that CQ could block the production of proinflammatory cytokines and the proliferation of monocytes, macrophages, and lymphocytes ([@B50]). The next year, a randomized, double-blind, placebo-controlled clinic trial from Singapore (registration number: NCT01078779) ([@B17]) have verified that CQ did not show protective efficacy against influenza infection (HIN1), although CQ was confirmed viable against both H1N1 and H3N2 influenza strains *in vitro* ([@B25]). Soon afterwards, CQ was test to affect intracellular exocytic pathways by increasing endosomal pH against dengue virus type 2 (DENV-2). The group of Farias KJ verified that 50 μg/ml of CQ could significantly inhibit of DENV-2 load in infected Vero and C6/36 cells production in 2013 ([@B25]). The large outbreak of Ebola virus (EBOV) disease in parts of West Africa which was first recognized in March 2014 ([@B27]). CQ was honorably repurposed as a potential candidate for treating EBOV. Although it was suggest the replication of EBOV was impaired by CQ *in vitro*, it might not be affected *in vivo*, especially in EBOV-infected guinea pig model ([@B19]). CQ can reduce the number of Zika-infected cells *in vitro*, and inhibits virus production and cell death promoted by Zika infection without cytotoxic effects ([@B16]). Then it has been shown in the mice model that CQ can cut off Zika virus from the mother-fetal pathway of vertical infection in 2016 ([@B16]). Up to now, CQ was verified effective against COVID-19 *in vitro* ([@B8]) *via* influencing bis (monoacylglycero) phosphate entry through hijacking of the endocytic pathway.

![The antiviral development history of CQ.](fphar-11-01167-g003){#f3}

###### 

The development of CQ against different type of virus and main mechanism behind the effect.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug   Virus                        Cells                                                                                                Main mechanism                                                                                                                                                                                                                                                                                                        Year         Ref
  ------ ---------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ -------------------------
  CQ     Borna disease virus          C6 rat glioma                                                                                        The mechanism of borna disease virus entry into C6 rat glioma cells were involved in pH-dependent fusion after internalization of the virion by endocytosis, while CQ could prevent endosomal acidification to inhibit the entry of borna disease virus.                                                              1998         ([@B28])

  CQ     SARS-CoV                     Vero,Vero E6                                                                                         CQ inhibited the infection and transmission of SARS-CoV *via* increasing endosomal pH, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.                                                                                                                                               2002--2006   ([@B31]; [@B55]; [@B2])

  CQ     Avian leukemia virus         293T, DF-1 chicken embryonic\                                                                        CQ accumulated in endocytic compartments and increases the endosomal pH to reduce the entry of pseudotyped ALV type B.                                                                                                                                                                                                2003         ([@B18])
                                      fibroblasts                                                                                                                                                                                                                                                                                                                                                                                                                             

  CQ     HIV-1                        MT-4                                                                                                 CQ has been shown to interfere with viral replication by impairing the glycosylation machinery in the Golgi that would direct trafficking and maturation of nascent viral proteins.                                                                                                                                   2004--2006   ([@B55]; [@B56])

  CQ     Chikungunya virus            Vero                                                                                                 The mechanism of CQ to inhibit the CHIKV infection in Vero cells involving the early stages of infection                                                                                                                                                                                                              2007-2010    ([@B32])

  CQ     Influenza infection (HIN1)   A549                                                                                                 Although CQ active against HIN1 *in vitro*, it did not prevent the weight loss associated with HIN1 infection in mice after challenge with viruses expressing an H1 or H3 hemagglutinin protein.                                                                                                                      2007         ([@B17]; [@B62])

  CQ     Influenza infection (H3N2)   MDCK                                                                                                 There was a clear correlation between the EC~50~ of CQ *in vitro* and the electrostatic potential of the HA subunit mediating the virus/cell fusion process.                                                                                                                                                          2007         ([@B17])

  CQ     Dengue virus type 2          Vero, C6/36 cells                                                                                    CQ affected intracellular exocytic pathways by increasing endosomal pH against dengue virus type 2.                                                                                                                                                                                                                   2013         ([@B25])

  CQ     Ebola virus                  Vero, Vero 76                                                                                        CQ and related compounds must affect a process downstream of cell binding. These observations are consistent with CQ arresting endosomal trafficking from the early to late endosome, which causes accumulation of virus that does not progress to the late endosome as normal, resulting in an abortive infection.   2014         ([@B41])

  CQ     Zika virus                   Vero, human brain microvascular endothelial cells, human neural stem cells, and mouse neurospheres   CQ reduces the number of Zika-infected cells *in vitro*, and inhibits virus production and cell death promoted by Zika infection without cytotoxic effects. In addition, CQ treatment partially reveres morphological changes induced by Zika infection in mouse neurospheres.                                        2016         ([@B16])

  CQ     COVID-19                     Vero E6                                                                                              CQ could influence the bis (monoacylglycero) phosphate entry through hijacking of the endocytic pathway to affect viral replication.l                                                                                                                                                                                 2020         ([@B8])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Clinical Trials of CQ Against COVID-19 in China {#s2_3}
---------------------------------------------------

Based on the urgent need of current clinical treatment, on 18^th^ February 2020, the general office of the national health commission of China published the "new coronavirus pneumonia diagnosis and treatment guideline (the sixth edition)" to increase CQ into the section of antiviral treatment drugs within this guideline. Here, we list the clinical trials of CQ against COVID-19 in China. There are 14 programs aimed to treat the various degree of COVID-19 in clinic, which divided by clinic classification. The clinic classifications are list as: the mild, normal, severe, and critical type. Consequently, the specific define of the above types of patients with COVID-19 are displayed:

\(1\) The mild type of patients with COVID-19.

The clinical symptoms were mild, and there was no sign of pneumonia on lung imaging.

\(2\) The normal type of patients with COVID-19.

Patients with fever, or/and respiratory symptoms, meanwhile the lung imaging with pneumonia.

\(3\) The severe type of patients with COVID-19.

In accordance with any of the following clinic symptoms: Shortness of breath, RR≥30 times/min; In resting state, oxygen saturation is less than 93%; Partial arterial oxygen pressure (Pa0~2~)/absorption oxygen concentration (Fi0~2~)≤300mgHg (The areas with high altitudes (over 1000 meter) shall be corrected for Pa0~2~/Fi0~2~ according to the following formula: Pa0~2~/F10~2~ x\[atmospheric pressure (mmHg)/760\]); The lesion progression with pulmonary imaging more than 50% within 24 to 48 h.

\(4\) The critical type of patients with COVID-19.

Meet one of the following clinic symptoms: Respiratory failure, mechanical ventilation; Shock; Combined with other organ failure, requiring intensive care unit.

Until now, there are 14 clinic trials of CQ against COVID-19 in China supplying in [**Table 2**](#T2){ref-type="table"}, which aimed to cover the all clinic classification of COVID-19. The details of inclusion criteria and exclusion criteria were supplied in the [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}, which could provide convenient reference for CQ-related clinical trials against COVID-19 in the near future. Among those above mentioned clinic trails, four were canceled by the investigator due to some objective factors. Herein, 10 programs are still ongoing. The duration of study therapy varies from one study to another (from 3 to 12 months). All the type of the clinical trial belongs to the "Intervention study". Obviously, we focus on the specific dosage of CQ in the treatment of COVID-19 either in alone or in combination usage. Only three (3/14, 21.43%) studies have provided the usage and dosage of CQ against COVID-19. The one route is *via* inhaled route (registration number: ChiCTR2000029975), the others are by oral administration (registration number: ChiCTR2000029992 and ChiCTR2000030054). The regimen of CQ in the inhaled administration is 150 mg/q12h, which could be inferred that 300 mg per day of CQ could be into the blood without the loss caused by gastro-intestinal tract. However, the regimen of CQ *via* the oral administration was 1g for 2 days, and from the 3^rd^ day was 0.5 g for 12 days. Basing on these details reported in the studies, the dosage of CQ against COVID-19 is at least above 300 mg per day and 500 mg per day *via* inhaled administration and oral administration, respectively, within treating cycle from 7 to 14 days. Although the outcomes of these clinic trials are not declared because of these programs are still ongoing, most of these studies have promised that the time of sharing individual participant data (IPD) will be within 6 months after the trial complete.

###### 

The list of clinical trials of CQ against COVID-19 in China.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Number   Registration number            Registration name                                                                                                                                                    Type of clinical trial   Registration date   Group                                                                                                                                                 Progress                                                                                                                                                                     Anticipated execute time       
  -------- ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ---------------------------------------------------------------------------
  1        ChiCTR2000029609               A prospective, open, multicenter clinical study on the treatment of COVID-19 with chloroquine phosphate                                                              Intervention study       6/2/2020            Mild-moderate chloroquine group: chloroquine phosphate was taken by oral\                                                                             Mild-moderate group Lopinavir/ritonavir group: oral Lopinavir/ritonavir\                                                                                                     Not yet recruiting.            From 2020-02-10 To 2020-12-31.\
                                                                                                                                                                                                                                                            Mild-moderate combination group: chloroquine phosphate plus Lopinavir/ritonavir was taken by oral\                                                    Severe-group Lopinavir/ritonavir group: oral Lopinavir/ritonavir                                                                                                                                            The time of sharing IPD will be within 6 months after the trial complete.
                                                                                                                                                                                                                                                            Severe-chloroquine group: chloroquine phosphate was taken by oral                                                                                                                                                                                                                                                                                                 

  2        ChiCTR2000029826               A randomized, double-blind, parallel-controlled study of chloroquine phosphate combined with standard therapy versus standard therapy for severe/critical COVID-19   Intervention study       14/2/2020           Phosphoric chloroquine: two tablets phosphoric chloroquine bid                                                                                        Placebo two tablets placebo bid                                                                                                                                              Canceled by the investigator   From 2020-02-17 To 2020-03-17

  3        ChiCTR2000029837               A randomized, double-blind, parallel-controlled study of chloroquine phosphate combined with standard therapy versus standard therapy for mild/normal COVID-19       Intervention study       15/2/2020           Phosphoric chloroquine: two tablets phosphoric chloroquine bid                                                                                        Placebo two tablets placebo bid                                                                                                                                              Canceled by the investigator   From 2020-02-17 To 2020-03-17

  4        ChiCTR2000029935               Single-arm clinical study on the treatment of COVID-19 with chloroquine phosphate                                                                                    Intervention study       16/2/2020           Treated with conventional treatment combined with chloroquine phosphate                                                                               Conventional therapy                                                                                                                                                         Recruiting                     From 2020-02-06 To 2021-02-06\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The time of sharing IPD will be within 6 months after the trial complete.

  5        ChiCTR2000029939               A single blind, randomized, controlled clinical trial of chloroquine phosphate tablets in the treatment of COVID-19                                                  Intervention study       16/2/2020           Conventional treatment with chloroquine phosphate                                                                                                     The conventional treatment group will be treated according to the guidance of the "Diagnosis and Treatment Scheme of COVID-19" published by the National Health Commission   Recruiting                     From 2020-02-06 To 2021-02-06\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The time of sharing IPD will be within 6 months after the trial complete.

  6        ChiCTR2000029975               Single-arm clinical study on the treatment of COVID-19 with chloroquine phosphate                                                                                    Intervention study       18/2/2020           In addition to the routine treatment, add 150 mg chloroquine phosphate dissolved in 5 ml of normal saline, q12h, inhaled by atomization for 1 week.   Conventional therapy                                                                                                                                                         Not yet recruiting.            From 2020-02-24 To 2020-05-31\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The time of sharing IPD Within 6 months after the trial complete

  7        ChiCTR2000029988               Chloroquine phosphate treatment for severe COVID-19                                                                                                                  Intervention study       18/2/2020           Chloroquine Phosphate                                                                                                                                 Conventional therapy                                                                                                                                                         Recruiting                     From 2020-02-13 To 2020-05-31\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The time of sharing IPD will be within 6 months after the trial complete.

  8        ChiCTR2000029992               A prospective, open randomized controlled trial of chloroquine phosphate and hydroxychloroquine sulfate in patients with COVID-19                                    Intervention study       18/2/2020           Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2 g bid for 14 days\                                                                   Recommended treatment plan for novel coronavirus pneumonia severe and critical cases                                                                                         Not yet recruiting.            From 2020-02-17 To 2020-05-20\
                                                                                                                                                                                                                                                            Chloroquine phosphate gloup: The first dose of chloroquine phosphate was 1 g for 2 days, and the 3^rd^ day was 0.5 g for 12 days                                                                                                                                                                                                                                  The time of sharing IPD will be within 6 months after the trial complete.

  9        ChiCTR2000030031               A randomized, double-blind, parallel-controlled study of chloroquine phosphate combined with standard therapy versus standard therapy for mild/normal COVID-19       Intervention study       21/2/2020           Phosphoric chloroquine: two tablets phosphoric chloroquine bid                                                                                        2 tablets placebo BID                                                                                                                                                        Canceled by the investigator   From 2020-02-20 To 2021-03-20

  10       ChiCTR2000030054\              An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel COVID-19                      Intervention study       22/2/2020           Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2g bid for 14 days\                                                                    Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan                                                                                      Not yet recruiting.            From 2020-02-22 To 2020-05-21\
           (Retrospective registration)                                                                                                                                                                                                                     Chloroquine phosphate gloup: The first dose of chloroquine phosphate was 1 g for 2 days, and the 3^rd^ day was 0.5 g for 12 days                                                                                                                                                                                                                                  The time of sharing IPD will be within 6 months after the trial complete.

  11       ChiCTR2000030417               Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel COVID-19                                            Intervention study       01/3/2020           Combined standard therapy of chloroquine phosphate aerosol inhalation solution                                                                        Water for injection atomization inhalation combined with standard therapy                                                                                                    Canceled by the investigator   From 2020-03-01 To 2020-06-30

  12       ChiCTR2000030718\              Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel COVID-19                                                                             Intervention study       11/3/2020           Chloroquine phosphate                                                                                                                                 Conventional therapy                                                                                                                                                         Recruiting                     From 2020-02-12 To 2020-05-30\
           (Retrospective registration)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The time of sharing IPD Real time access

  13       ChiCTR2000030987               Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel COVID-19                                                          Intervention study       20/3/2020           Experimental group 1: the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group\                                        Placebo group                                                                                                                                                                Recruiting                     From 2020-03-05 To 2020-06-25\
                                                                                                                                                                                                                                                            Experimental group 2: the oral trial drug favipiravir tablet                                                                                                                                                                                                                                                                                                      The time of sharing IPD will be within 6 months after the trial complete.

  14       ChiCTR2000031204\              A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel COVID-19                                       Intervention study       24/3/2020           Chloroquine phosphate tablets *via* oral                                                                                                              Placebo                                                                                                                                                                      Recruiting                     From 2020-01-30 To 2020-04-30\
           (Retrospective registration)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The time of sharing IPD will be within 6 months after the trial complete.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

bid, bis in die; IPD, information of participant data.

Potential Risk of CQ in Clinic to Treat COVID-19 {#s2_4}
------------------------------------------------

According to the "Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia" edit by [@B61], the dosage and treatment plan of CQ against COVID-19 are 500 mg/bid within a treating cycle of 10 days. If severe gastrointestinal reactions appear, the dosage should be reduced to 500 mg/qd or even stopping administration. If the nucleic acid from the pharynx swab turns negative and lasts for at least 3 days as negative during the CQ treatment, the plan of withdrawal can be considered. But the minimum program of CQ treatment requires at least 5 days.

Based on previous reports, CQ is rapidly absorbed from the gastro-intestinal tract when administration *via* oral route ([@B24]). The average oral bioavailability is approximately 89% with a relatively uncertain half-life as long as 5-60 days ([@B21]), with a median half-life of 21-30 days. The clinical lethal dose of CQ was reported as 3-5 g according to the reports by New England Journal Medicine in 1988 ([@B52]). If the adverse reactions from CQ emerged, the combining early mechanical ventilation with diazepam and epinephrine *via* intravenous infusion might be effective way to treat CQ poisoning ([@B54]). Furthermore, ammonium chloride can be used to accelerate excretion and reduce the concentration of CQ in plasma; owing to CQ is an alkaloid ([@B54]).

What's more, reviewing the past clinical experience by CQ against antiviral, it might be emerged unexpected results contrary to our wish. For example, as above mentioned, CQ exhibited a good antiviral effect on MDCK cells infected with human influenza a virus H1N1 and H3N2, while the clinical trial (registration number: NCT01078779) have not further confirmed this result. This clinical trial recruited 1516 cases of H1N1 eligible participants ([@B50]). In this trial, CQ was administered at the dosage of 500 mg/qd for the 1^st^ week. Then the participants were taken 500 mg once a week to complete a total course of 12 weeks. The data confirmed that CQ did not prevent infection with influenza, while the incidence of adverse reactions was higher (P \< 0.0001). The adverse reactions containing headache, dizziness, nausea, diarrhea, and blurred vision were verified positive with CQ. Herein, the treating regimen of CQ against COVID-19 in China might be at risk and called for more monitoring. A blood sample concentration of CQ suggests monitoring continuously.

Brief Introduction of HCQ on the Virus {#s2_5}
--------------------------------------

The main development of HCQ against virus was very similar with CQ, owing to the similarity from chemical structure. In other words, if CQ played positive effect against some specific virus, HCQ would be considered naturally and studied simultaneously. The 3D structure of HCQ was exhibited in [**Figure 3**](#f3){ref-type="fig"}. Indeed, HCQ was also verified the activity of antivirus, such as HIV-1 ([@B13]), SARS-CoV ([@B6]), Zika Virus ([@B36]), CHIKV ([@B44]), DENV (L. F. [@B64]), COVID-19 ([@B29]), and so on. Consequently, we shall pay more attention to the usage and dosage of HCQ in clinic, especially against COVID.

The Clinical Trials of HCQ Against COVID-19 in China {#s2_6}
----------------------------------------------------

Similarly, we searched the website of the Chinese clinical trials registry and found that there are currently eleven approved clinical studies under way, which contain two repetitive studies within in CQ-related trials (registration number: ChiCTR2000029992 and ChiCTR2000030054) and showing in [**Table 3**](#T3){ref-type="table"}. The details of inclusion criteria and exclusion criteria of HCQ-related trails were also supplied in the [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}, which would be also helpful for clinicians to consult. As shown in [**Table 3**](#T3){ref-type="table"}, there is only one program (1/11, 9.09%) aiming to "observational study". Ten programs (10/11, 91.01%) are focused on the "intervention effect of HCQ against COVID-19". In fact, three studies have canceled by the investigator due to lack of eligible participants. The anticipated execute time of HCQ-related study varies from 1 to 6 months, which are shorter than the trials of CQ-based treatment study. Back to the point on dosage of HCQ against COVID-19, five studies (5/11, 45.45%) supply the accurate dose of HCQ among these clinic trials. In the study of ChiCTR2000029559 and ChiCTR2000029740, 0.2 g bid of HCQ *via* oral administration are given. The maximum dose of HCQ can be calculated as 400 mg per day without the key factor, that is, specific treating cycle. In the study of ChiCTR2000029992 and ChiCTR2000030054, the duration time of HCQ against COVID is exhibited, that is 14 days, with the similar regimen comparing with study of ChiCTR2000029559 and ChiCTR2000029740.

###### 

The list of clinical trials of HCQ against COVID-19 in China.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Number   Registration number   Registration name                                                                                                                                 Type of clinical trial   Registration date of clinical trial   Group                                                                                                                                                                                                               Progress                                                                                  Anticipated execute time            
  -------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------- ------------------------------------------------------------------
  1        ChiCTR2000029559      Hydroxychloroquine sulfate in patients with COVID-19                                                                                              Intervention study       4/2/2020                              Hydroxychloroquine 200 mg bid *via* oral                                                                                                                                                                            Placebo group: Starch pill bid *via* oral                                                 Complete                            From2020-01-31 To 2020-02-29\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The time of sharing IPD Within 6 months after the trial complete

  2        ChiCTR2000029740      Study on the effectiveness of hydroxychloroquine sulfate in treating COVID-19                                                                     Intervention study       11/2/2020                             Hydroxychloroquine 200 mg bid *via* oral                                                                                                                                                                            Conventional therapy                                                                      Recruiting                          From 2020-02-11 To 2020-02-29\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The time of sharing IPD Within 6 months after the trial complete

  3        ChiCTR2000029760      Study on the effectiveness of hydroxychloroquine sulfate in treating mild/normal COVID-19                                                         Intervention study       12/2/2020                             Hydroxychloroquin                                                                                                                                                                                                   Lopinavir/Ritonavir                                                                       Canceled due to lack of patients.   From 2020-02-12 To 2020-08-11 

  4        ChiCTR2000029761      Study on the effectiveness and safety of hydroxychloroquine sulfate in treating mild/normal COVID-19                                              Intervention study       12/2/2020                             Low-dose group:Low-dose hydroxychloroquine and conventional therapy\                                                                                                                                                Conventional therapy                                                                      Canceled due to lack of patients.   From 2020-02-13 To 2020-04-30
                                                                                                                                                                                                                                                  Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy\                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                  High-dose group:High-dose hydroxychloroquine and conventional therapy                                                                                                                                                                                                                                                                             

  5        ChiCTR2000029762      Study on the effectiveness and safety of hydroxychloroquine sulfate in treating severe/critical COVID-19                                          Intervention study       12/2/2020                             Conventional treated with hydroxychloroquine                                                                                                                                                                        Conventional treatment                                                                    Canceled due to lack of patients.   From 2020-02-12

  6        ChiCTR2000029868      Multicenter clinical study on the treatment of COVID-19 with hydroxychloroquine sulfate                                                           Intervention study       15/2/2020                             Hydroxychloroquine sulfate 1200 mg daily for 3 days followed by a maintenance dose of 800 mg daily (total treatment duration: two or 3 weeks for patients with mild to moderate or severe disease, respectively).   Conventional treatment                                                                    Complete                            From 2020-02-06 To 2020-06-30\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The time of sharing IPD Within 6 months after the trial complete

  7        ChiCTR2000029992      A prospective, open randomized controlled trial of chloroquine phosphate and hydroxychloroquine sulfate in patients with COVID-19                 Intervention study       18/2/2020                             Chloroquine phosphate gloup: Chloroquine phosphate 1.0 g with 2 days for the first dose, 0.5 g for 12 days from the 3^rd^ day\                                                                                      Recommended treatment plan for severe and critical cases in COVID-19                      Not yet recruiting.                 From2020-02-17 To 2020-05-20\
                                                                                                                                                                                                                                                  Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2 g BID for 14 days                                                                                                                                                                                                                                                                The time of sharing IPD Within 6 months after the trial complete

  8        ChiCTR2000030054      An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel COVID-19   Intervention study       22/2/2020                             Hydroxychloroquine sulfate gloup: Hydroxychloroquine sulfate 0.2 g BID for 14 days\                                                                                                                                 Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan   Not yet recruiting.                 From 2020-02-22 To 2020-05-21\
                                                                                                                                                                                                                                                  Chloroquine phosphate gloup: The first dose of chloroquine phosphate was 1 g for 2 days, and the 3^rd^ day was 0.5 g for 12 days                                                                                                                                                                                                                  The time of sharing IPD Within 6 months after the trial complete

  9        ChiCTR2000031174      Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel COVID-19                                              Intervention study       23/3/2020                             Hydroxychloroquine                                                                                                                                                                                                  Placebo                                                                                   Not yet recruiting.                 From 2020-03-23 To 2020-09-30\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The time of sharing IPD Within 6 months after the trial complete

  10       ChiCTR2000031782      A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel COVID-19                                    Observational study      10/4/2020                             /                                                                                                                                                                                                                   /                                                                                         Not yet recruiting.                 From 2020-04-10 To 2020-06-30\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The time of sharing IPD Within 6 months after the trial complete

  11       ChiCTR2000032487      Study for using sulfate in the prevention and control of novel COVID-19 in high and low prevalence communities                                    Intervention study       29/4/2020                             Hydroxychloroquine                                                                                                                                                                                                  Placebo                                                                                   Not yet recruiting.                 From 2020-03-01 To 2020-09-30\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    The time of sharing IPD Within 6 months after the trial complete
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

bid, bis in die; IPD, information of participant data.

To our relief, there are two trials, which have been published on 10^th^, April, 2020 from Chen and co-workers (registration number: ChiCTR2000029559) ([@B12]) and 14^th^, May, 2020 from the group of Tang (registration number: ChiCTR2000029868) ([@B60]), respectively.

In the trial of ChiCTR2000029559, 62 patients who met the trial criteria were randomly assigned in two groups. Patients in both groups received the standard treatment (oxygen therapy, antiviral agents, antibacterial agents, and immunoglobulin, with or without corticosteroids) as the authors depicted. The patients in the HCQ treatment group received additional oral HCQ for 400 mg/d (200 mg/bid) for 5 days continuously, while patients in the control group just with the standard treatment only. The results showed that pneumonia was improved in 67.7% (42/62) of patients, with 29.0% moderately absorbed and 38.7% significantly improved verified by chest CT. For adverse effects, it should be noted that there were two patients with mild adverse reactions in the HCQ treatment group. The one patient developed rash, the other one experienced a headache. None severe side effects appeared in HCQ treating group. This trial did give us an exciting outcome, while the small number of participants and short of duration time was the disadvantage in this study.

In the trial of Tang's colleagues ([@B60]), HCQ is administrated at a loading dose of 1200 mg daily for 3 days followed by a maintenance dose of 800 mg daily during 2 or 3 weeks for patients with mild to moderate or severe type of patients with COVID-19, respectively. Totally, 150 patients have been recruited; in which 148 belong to mild to moderate type of patients with COVID-19 and two were geared to severe type of patients with COVID-19. As the result, the treatment of HCQ did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate COVID-19. To make matters worse, adverse events were higher in HCQ recipients than in non-recipients. The most common adverse event in the HCQ recipients was diarrhoea, reported in 7/70 (10%) patients. Other non-serious adverse events as the authors depicted were vomiting 2/70 (2.86%), kidney injury 1/70 (1.43%), nausea 1/70 (1.43%), abdominal discomfort 1/70 (1.43%), sinus bradycardia 1/70 (1.43%), hypertension 1/70 (1.43%), and so on, which never been found in HCQ non-recipients. Two HCQ recipients reported serious adverse event, such as disease progression and upper respiratory tract infection. It's worth noting that the usage of HCQ was in combination with antiviral agents (arbidol, virazole, lopinavir/ritonavir, oseltamivir, entecavir) rather than in alone in this trial. Herein, the drug interaction needs to be considering further, while this trial without the relevant design about the relationship between HCQ and antiviral agents. Basing on some reports, the lopinavir/ritonavir, atazanavir/ritonavir may increase exposure by inhibition of CYPs enzymes 2C8, 3A4, and 2D6. Consequently, increase the risk of QTc interval prolongation when concurrent use with HCQ ([@B1]).

According to the result of literature research, we found an article written in Chinese language, which publish a latest clinic trial about HCQ (registration number: NCT04261517) ([@B11]). Herein, we shall also share the usage and dosage about this study. Only 30 patients confirmed with mild type or normal type of COVID-19 from Shanghai, China, were enrolled in this study. Patients were randomly assigned in two groups, that is, with or without HCQ treatment group. The treating regimen was that 400 mg qd of HCQ for 5 days. The total dosage of HCQ was similar with Chen's study ([@B12]), while the frequency was different. The findings from this study indicated that there were no significant differences in the improvement of negative conversion between standard of care alone group and HCQ treatment group. What's more, the incidence of gastrointestinal adverse reactions is higher in HCQ treatment group.

Another report from Nuffield Department of Population Health University of Oxford declared a large randomized controlled trial \[[@B51]\]. In this trial, there was no significant difference in the primary endpoint of 28-day mortality \[25.7% HCQ vs. 23.5% usual care; hazard ratio 1.11 (95% confidence interval 0.98-1.26); p=0.10\]. Meanwhile, there was also no evidence of beneficial effects on hospital stay duration or other outcomes. Subsequently, the authors discontinued randomization in the HCQ arm.

According to the latest news from WHO on 4^th^ July, the "SOLIDARITY" trial will discontinue the HCQ arm based on evidence from the current outcome from "SOLIDARITY" clinical trial (<https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19>). The interim results do not provide solid evidence of increased mortality caused by HCQ, while some associated safety findings increased the deep concern about HCQ against COVID-19. WHO also announced that this decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of HCQ in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19.

A randomized, double-blind, placebo-controlled trial emphasizing the effect of HCQ as postexposure prophylaxis from New England Journal of Medicine declared that the incidence of new illness compatible with COVID-19 did not differ significantly between participants receiving HCQ (11.8%, 49/414) and those receiving placebo (14.3%, 58/407) ([@B7]). The treating regimen of HCQ was 800 mg once, followed by 600 mg in 6 to 8 h, then 600 mg daily for 4 additional days. The dosage in this trial was higher than those in China. The reasons might be conducted as two sides. The one reason might be different ethnicity in the patient population. In this trial, patients were across the United States and parts of Canada, which belongs to the white race. The other reason might be related with the average weight of recruited patients. Recommendations on screening for HCQ retinopathy by the American Academy of Ophthalmology were revised in 2016. These revised recommendations suggested that the maximum daily dose should be based on real body weight ([@B42]).

To sum up, the higher dosage of HCQ might be brought out with more adverse reaction in clinic against COVID-19. The positive effect of HCQ on COVID-19 were controversial according to the current outcome.

Potential Risk of HCQ in Clinic to Treat COVID-19 {#s2_7}
-------------------------------------------------

According to the usage of HCQ in clinic, the major risks of HCQ in clinic were retinal toxicity and ophthalmologic adverse symptom ([@B47]). Herein, renal impairment (such as eGFR \<= 30 ml/min/1.73 m^2^) have been taken into consideration in the exclusion criteria among most of CQ-based and HCQ-based clinic trials, as exhibited in [**Supplementary Tables 1**](#SM1){ref-type="supplementary-material"} and [**2**](#SM1){ref-type="supplementary-material"}. Retinal toxicity from CQ and HCQ has been recognized for many years ([@B22]). Although HCQ has been demonstrated less side effect compared to CQ *via* ocular administration, retinal toxicity to HCQ should not to be neglected owing to it might continue to progress even after cessation of therapy. What's more, the increasing risk of visual loss were verified concerning with retinal toxicity ([@B45]).The retinal toxicity was associated with duration of HCQ use, daily HCQ dosage, and presence of kidney disease ([@B46]). Proper dosing of maximum 5 mg/kg of HCQ *via* oral administration was generally accepted ([@B33]). As aforementioned, the maximum daily dose should be based on real body weight ([@B42]). The daily dosage of HCQ on lupus erythematosus (SLE) and rheumatoid arthritis (RA) were at much higher doses (up to 600 mg/d or 800 mg/d) to treat these autoimmune diseases ([@B4]). The clinical trials related with HCQ were a lot, while the therapeutic effect on virus was few. In1997, a randomized, double-masked trial in which HCQ (800 mg/d) or zidovudine (500 mg/d) was given to 72 HIV-l-infected patients for 16 weeks orally in New York ([@B59]). The data have shown that no adverse reactions were observed in either the HCQ or zidovudine group in the study medications with levels of recoverable HIV-l RNA decreasing in both groups. Furthermore, the level of interleukin-6 and serum immunoglobulin G, which related with HIV-l replication in chronically infected cells and might be associated with the development of malignancies and autoimmunity, were significantly decreased in the HCQ treated group but not in the zidovudine group. Basing on the results of this clinic trial, the dosage of 800 mg/d for continuously 16 weeks medication of HCQ was well tolerated and HCQ suppressed HIV-l replication in infected patients.

A long-term, multinational, network cohort and self-controlled case series study has reported serious heart rhythm problems with HCQ, especially when taken at high doses or in combination with the antibiotic azithromycin (registration number: EUPAS34497). The study period started from 01/09/2000 and ended in 2020 with participants with a history of RA. The outcome could be drew as that short-term HCQ treatment is safe, while addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length. Herein, the authors call for caution if such combination is to be used in the management of COVID-19 ([@B37]).

Despite the adverse risk of HCQ, some reports have bared out HCQ showed protective effect on coronary artery, dyslipidemia, diabetes mellitus, preeclampsia, and chronic inflammatory diseases and so on. A clinical trial in Taiwan (registration number: CSMUH CS15134) confirmed that HCQ users versus non-users for coronary artery diseases events was 0.32 (95% CI, P \<0.01) over up to 10 years ([@B30]). This study revealed that RA patients taking with HCQ could decrease coronary artery diseases risk, while the dosage of HCQ was not clearly. A double-blind, randomized, out-patient study (registration number: CTRI/2010/091/006138) in India which was conducted in 328 patients with primary dyslipidemia patients, was demonstrated that HCQ could emerge as a potential drug for combination with statins for treatment of dyslipidemia ([@B49]). The benefits of HCQ combinational with rosiglitazone ([@B26]), metformin ([@B34]), acarbose ([@B14]), indicated that a reduction in diabetes risk of up to 77% for patients, who had been taken HCQ for at least 4 years. HCQ was used at a low and fixed dose (200 mg/d) to ensure that the daily dose did not exceed 6.5 mg/kg. A latest retrospective cohort study conducted in 2019, aimed to investigate the impact of HCQ on pregnancy with SLE ([@B57]). This study included 151 pregnancies in 122 patients with SLE (80 pregnancies in the HCQ treatment group and 71 pregnancies without HCQ medication). The results revealed that preeclampsia was significantly less complicated (P=0.032) in the HCQ treatment group compared with HCQ non-treatment group. Moreover, the data showed pregnancy outcomes in SLE patients could be improved in the HCQ treatment group with about 90% reduction of preeclampsia. However, in this study, the specific dosage of HCQ was not supplied. Another large observational cohort study for patients with RA in China, the incidence rate of chronic inflammatory diseases was lower in HCQ users than in HCQ nonusers (P=0.01) with the prescribed daily dose (≦200, 201-400, or\>400 mg) ([@B67]).

Conclusions {#s3}
===========

Even though WHO declared the "SOLIDARITY" trial would discontinue the HCQ arm based on evidence from the current outcome from "SOLIDARITY" clinical trial to the conduct of the Solidarity trial in hospitalized patients and would not affect the possible evaluation in other studies of HCQ in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19, about 104 clinical trials are still ongoing in different countries to assess the potential effects of CQ and/or HCQ against COVID-19, according to the latest reports ([@B35]). We may infer that although the clinic results are controversial of HCQ against COVID-19 currently, the scientists don't give up the opportunities to explore the real mechanism, effect, and toxicity of HCQ. According to the research progress, the outcome of HCQ in clinic shows controversial results. We call for carrying out large-scale, medium- and long-term clinical trial of HCQ to verify whether HCQ being with the function against this undesired virus on human beings. Meanwhile, the lower dosage (200 mg/bid) of HCQ with short treating cycle (5 days) is worth to be considered for future studies.
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